Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

Related Keywords

Texas ,United States ,Dallas ,Hungary ,Budapest ,Milan ,Lombardia ,Italy ,Isabella Ciccone ,Renato Mantegazza ,Neuromuscular Diseases Department ,European Academy Of Neurology ,Muscular Dystrophy Association Clinical Scientific Conference ,Myasthenia Gravis Activities ,Daily Living ,Prescription Drug User Fee Action ,European Academy ,Fondazione Istituto Neurologico ,Myasthenia Gravis Composite ,Myasthenia Gravis Quality ,Dystrophy Association Clinical ,Scientific Conference ,Generalized Myasthenia Gravis ,Zilucoplan ,Mg Adl ,Raise Xt ,Qmg Score ,